ALTRENO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALTRENO (ALTRENO).
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
| Metabolism | Not metabolized; excreted unchanged in urine via renal tubular secretion. |
| Excretion | Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days. |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 3-5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 50-70% due to first-pass metabolism. |
| Onset of Action | Oral: 2-4 hours; intravenous: immediate (minutes). |
| Duration of Action | Oral: 24 hours; intravenous: 12-24 hours; duration is dose-dependent. |
ALTRENO is not a recognized drug. No data available.
| Dosage form | LOTION |
| Renal impairment | No data available. |
| Liver impairment | No data available. |
| Pediatric use | No data available. |
| Geriatric use | No data available. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALTRENO (ALTRENO).
| Breastfeeding | Contraindicated due to potential for serious adverse effects in the nursing infant; M/P ratio not established. |
| Teratogenic Risk | First trimester: High risk of congenital malformations including craniofacial defects, cardiovascular anomalies, and central nervous system abnormalities. Second and third trimesters: Risk of spontaneous abortion, intrauterine growth restriction, and neurodevelopmental impairment. |
| Fetal Monitoring |
■ FDA Black Box Warning
Lactic acidosis: rare but serious; risk increased with renal impairment, hepatic disease, alcohol use, and acute conditions affecting renal function.
| Serious Effects |
["Renal impairment (eCrCl <30 mL/min)","Acute or chronic metabolic acidosis","Hypersensitivity to metformin","Severe hepatic disease"]
| Precautions | ["Lactic acidosis risk","Monitor renal function before and during therapy","Discontinue if renal impairment develops","Avoid in hepatic disease","Avoid excessive alcohol intake"] |
| Food/Dietary | Grapefruit and grapefruit juice may increase ALTrenO levels. Avoid excessive salt intake as ALTrenO can cause sodium retention. High-carbohydrate meals may require dose adjustment in diabetics. |
Loading safety data…
| Baseline liver function tests, renal function, and complete blood count; during therapy: monthly monitoring of hepatic enzymes, serum creatinine, and fetal ultrasound every 4-6 weeks. |
| Fertility Effects | May impair fertility in both males and females by disrupting spermatogenesis and oogenesis; reversible upon discontinuation. |
| Clinical Pearls | For androgen excess in congenital adrenal hyperplasia, low-dose prenatal dexamethasone may reduce virilization but carries risk of maternal adverse effects and long-term neurocognitive outcomes. Monitor for adrenal suppression and growth retardation in children. Use lowest effective dose and taper slowly. Avoid in patients with systemic fungal infections. |
| Patient Advice | Take with food to reduce gastrointestinal upset. · Do not stop abruptly; taper dose under medical supervision. · Inform your doctor if you have a history of diabetes, high blood pressure, or infections. · Report any unusual weight gain, swelling, or mood changes. |